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Abstract
Background: This project was undertaken to generate a core set of items to develop classification 
criteria for scleroderma renal crisis (SRC) using consensus methodology.
Methods: An international, multidisciplinary panel of experts was invited to participate in a 3-round 
Delphi exercise developed using a survey based on items identified by a scoping review. In Round 1, 
participants were asked to identify omissions and clarify ambiguities regarding the items in the survey. 
In Round 2, participants were asked to rate the validity and feasibility of the items using Likert-type 
scales ranging from 1-9 (1= very invalid/unfeasible, 5 = uncertain, 9 = very valid/feasible). In Round 3, 
participants reviewed the results and comments of Round 2, and were asked to provide final ratings. 
Items rated as highly valid and feasible (both median scores ≥7) in Round 3 were selected as the 
provisional core set of items. A consensus meeting using nominal group technique (NGT) followed to 
further reduce the core set of items.
Results: Ninety-nine experts from 16 countries participated in the Delphi exercise. Of the 31 items in 
the survey, consensus was achieved on 13, including hypertension, renal insufficiency, proteinuria and 
hemolysis. Eleven experts took part in the NGT discussion, where consensus was achieved in 5 
domains: blood pressure, acute kidney injury, microangiopathic hemolytic anemia, target organ 
dysfunction, and renal histopathology. 
Conclusions: A core set of items that characterize SRC was identified using consensus methodology. 
This core set will be used in future data-driven phases of this project to develop classification criteria for 
SRC.
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Introduction
Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc) (1–
4). It is usually characterized by malignant hypertension and acute kidney injury (3). However, the 
clinical spectrum of SRC is broad, ranging from full-blown disease presenting as new onset accelerated 
arterial hypertension and rapidly progressive oliguric renal failure, to more modest elevations in blood 
pressure and renal dysfunction, and at times normotensive presentations. On the other hand, 
hypertension without uraemia, urinary abnormalities and/or mild uraemia attributable to other factors 
(e.g., concomitant comorbidities such as diabetes or exposure to nephrotoxic medications) are common 
in SSc (4,5). These conditions should not be confused with SRC. 
SRC is relatively rare, occurring in about 5% of all SSc patients (3). It is more common in 
patients with rapidly progressing diffuse cutaneous SSc (dcSSc) (11%) as compared to patients with 
limited cutaneous SSc (lcSSc) (4%) (6). SRC can be further sub-categorized into hypertensive or 
normotensive forms, representing approximately 90% and 10% of SRC cases, respectively (7,8).  
Historically, SRC was the leading cause of death in SSc (9). However, with the advent of angiotensin 
converting enzyme (ACE) inhibitors, mortality rates have decreased significantly (10,11). Nevertheless, 
one-year outcomes remain poor, with over 30% mortality and 25% of patients remaining dialysis-
dependent (12). There is an urgent need to undertake research to identify novel treatments and to 
improve outcomes of SRC.
In addition to heterogeneity and rarity, the absence of a gold standard and classification criteria 
are important challenges for research on SRC. To date, most studies of SRC have used ad hoc criteria 
that have varied considerably from study to study. In a scoping review of the literature, 40 original 
definitions of SRC, with significant heterogeneity among them, were identified (13). Only one study to 
date has partially validated criteria for SRC (12).  
The Scleroderma Clinical Trials Consortium (SCTC) SRC Working Group was created to 
develop classification criteria for SRC. The objective of this phase of the study was to generate a core 
set of items to define SRC using consensus methodology. Future studies using data-driven methods will 
be required to develop and validate classification criteria for SRC. Au
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Methods
A scoping review of the literature to identify items used to define SRC has been published (13). 
The results of this review were used to inform this project, which consisted of two phases: 1) a modified 
online Delphi exercise to develop provisional consensus on a core set of items to define SRC and 2) a 
consensus meeting using nominal group technique (NGT) to further reduce the core set. Ethics approval 
for this project was obtained from the Jewish General Hospital Research Ethics Board, Montréal, 
Quebec, Canada (Protocol # CODIM-MBM-17-104).
Phase 1: Delphi
A modified, online, 3-round Delphi exercise was conducted (14,15). Experts from the SCTC, 
European Scleroderma Trials and Research Group (EUSTAR), Canadian Scleroderma Research Group 
(CSRG) and Australian Scleroderma Interest Group (ASIG) were invited to participate. In addition, 
pathologists and nephrologists known through these organizations with interest in SRC were also invited 
to participate. Individuals interested in participating were asked to accept the invitation by return email. 
All individuals who accepted were then considered study participants, and thereby constituted the 
denominator for the participation rates.
The Delphi survey was developed and managed through the REDCap platform (Vanderbilt 
University, Nashville, Tennessee). In Round 1, consent to participate was obtained and demographic and 
personal information was collected on participants. Subsequently, Round 1 asked participants to 
consider the items identified in the scoping review and requested them to clarify ambiguities, identify 
omissions and provide comments. Items were modified accordingly. 
In Round 2, participants were asked to rate the scientific validity, empirical validity and 
feasibility of the items using Likert-type scales ranging from 1-9 (1= very invalid/unfeasible, 5 = 
uncertain, 9 = very valid/feasible) and to provide comments. Participants were provided links to full-text 
copies of the scoping review and all of the papers included therein. Scientific validity was defined as 
items supported by published literature and empirical validity as items supported by personal experience 
and knowledge of professional consensus. Feasibility was defined in terms of whether the item could be 
performed/tested in an easy or convenient matter. 
In Round 3, the results of Round 2 were presented using summary statistics, including medians 
and interquartile ranges, and bar graphs. Participants were also shown their answers and anonymized 
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comments from other participants from Round 2. The participants were then asked to provide their final 
rating on scientific validity, empirical validity and feasibility of the items. 
Consensus was defined as items rated highly scientifically valid and feasible (both median scores 
≥7) in Round 3, and for which there was no disagreement, calculated using the RAND/UCLA 
Appropriateness Method formula. Disagreement exists when the inter-percentile range (IPR: difference 
between the 30th and 70th percentiles) is larger than the IPR adjusted for symmetry (IPRAS), calculated 
as follows:
IPRAS = 2.35 + [Asymmetry Index x 1.5]
Derivation of the formula is shown in the RAND/UCLA Appropriateness Method handbook (16). 
Phase 2: NGT meeting
The second phase of this study was to reduce the number of items and achieve consensus using 
NGT (17). International experts, including rheumatologists, internists and nephrologists, were invited to 
participate in a 2-hour face-to-face meeting held in November 2017 in San Diego (California, USA). Dr. 
Dinesh Khanna moderated the discussion based on expertise and previous experience in the fields of 
SRC and NGT techniques (17,18). Each item from the Delphi was discussed in turn. Each panelist was 
invited to provide comments. At the end of the discussion, the panelists were asked to vote by a show of 
hands if the items should be included in the core set. A simple majority was required to include the item. 
During the NGT meeting, it became clear that some items required content expertise beyond 
rheumatology, internal medicine and nephrology. Thus, some items were conditionally included, 
pending further review with content experts. Experts in hematology, neurology, ophthalmology, and 
cardiology were then contacted and asked to provide input and published evidence to define items in 
those domains.
A final list of core set items (and their definitions) was compiled and circulated among the 
participants of the NGT meeting for final approval.
Results
Phase 1: Delphi 
We contacted 216 people with an interest in SRC of which 99 agreed to participate in the 
modified online Delphi exercise. Of those, 77 (78%), 60 (61%) and 69 (70%) participated in Rounds 1, 
2 and 3, respectively, and 49 (49%) completed all three rounds of the exercise. Participants were mainly 
rheumatologists (86%) with some internists, nephrologists and pathologists. Most participants worked as 
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clinicians for >11 years, with only a few having less than 10 years of experience (13%). The majority of 
participants were from the United States (35%) followed by Canada (11%); 16 other countries were also 
represented. 
A total of 31 items in 11 categories were included in the Delphi exercise. Of these, 13 items in 4 
categories (hypertension, renal insufficiency, proteinuria and hemolysis) achieved consensus in Round 3 
(median ratings > 7 on scientific validity and feasibility with no disagreement). Disagreement on 
feasibility was only present for hyper-reninemia. In any case, that item had not achieved consensus on 
feasibility either. Of note, all items that reached consensus in Round 2, also reached consensus in Round 
3 with no additional items reaching consensus in Round 3. However, the IQR for the majority of items 
became smaller in Round 3, demonstrating growing consensus. The median ratings and IQR for each 
item for Rounds 2 and 3 are presented in Table 1.
Phase 2: Nominal Group Technique meeting 
Seventeen international experts were invited to participate in a face-to-face NGT meeting. Six 
were not available. Thus, the panel consisted of 11 participants, 10 rheumatologists and 1 nephrologist, 
from the USA, Canada, United Kingdom, France, Netherlands and Australia. Prior to the NGT meeting, 
the 11 categories from the Delphi exercise were re-organized into 5 domains (hypertension, renal 
dysfunction [renal insufficiency, proteinuria, hematuria and hyper-reninemia], microangiopathic 
hemolytic anemia with thrombocytopenia, target organ dysfunction [encephalopathy, retinopathy and 
cardiac dysfunction] and renal histopathology). Prior to and at the meeting, it was agreed that items 
should be defined as much as possible according to evidence and/or international guidelines. Content 
experts in hematology, neurology, ophthalmology, and cardiology were contacted to provide input on 
definitions of items included in the core set.
The final core set of items and their definitions are presented in Table 2, and were approved by 
the NGT participants.
Discussion
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In this study, we generated a core set of items to classify SRC using consensus methodology. 
This core set includes 5 domains and 14 items. The definitions for each item were evidence-based or, in 
the absence of evidence, determined in consultation with content experts. 
The progress made to date to develop classification criteria for SRC demonstrates the importance 
of using the best evidence available. A scoping review of the literature identified 40 heterogeneous 
definitions of SRC using more than 40 items with variable definitions (13). The Delphi exercise led to 
consensus on 13 of these items. However, the need to go beyond consensus in the rheumatology 
community and to get the input of content experts emerged as a critical factor at the NGT meeting. Thus, 
the input from content experts was sought to finalize the core set. Proteinuria is a perfect example of 
how this approach allowed the core set to evolve. Indeed, low-level proteinuria is common in SSc (4), 
dipstick and urine protein-to-creatinine ratio are not reliable in AKI, proteinuria is not part the Kidney 
Disease Improving Global Outcomes (KDIGO) definition of AKI (19), and proteinuria would 
compromise specificity of SRC criteria. Thus, despite the fact that there was consensus to include 
proteinuria in the core set after the Delphi exercise, this item was excluded after the NGT meeting and 
discussion with nephrologists.
A core set of variables to define SRC was proposed by experts in 2003 (7). It included items for 
systolic and diastolic blood pressure, serum creatinine, proteinuria, hematuria, microangiopathic 
hemolytic anemia and renal histopathology. These are known as the Ancona criteria for SRC. Our core 
set has similarities to the Ancona criteria in particular with respect to blood pressure. However, there are 
also notable differences in defining acute kidney injury (including the exclusion of proteinuria and 
hematuria). In addition, our core set includes target organ dysfunction and a detailed histopathological 
description of SRC.
 In 2016, the UK Scleroderma Study Group proposed criteria for the diagnosis of SRC (20). The 
criteria were divided into categories: diagnostic criteria (essential) and supportive evidence (desirable) 
with blood pressure and AKI as the former, MAHAT, hypertensive retinopathy, hematuria, oliguria or 
anuria, renal biopsy consistent with SRC features and flash pulmonary edema as the latter. 
Discrepancies with our proposed criteria are found in the slightly modified cut-off values for blood 
pressure (150/85 mmHg versus 140/90 mmHg) and additionally, there is no noted rise in diastolic blood 
pressure, only >20 mmHg for systolic blood pressure which is lower than >30 mmHg proposed in this 
study. Further, the UK criteria included hematuria. Additionally, oliguria and flash pulmonary edema 
were proposed as stand-alone items whereas in our list, these items are grouped into the AKI and acute 
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heart failure definitions, respectively. Our core set provides a more in depth detailed definition for each 
item, specifically for AKI, MAHAT and renal histopathology. 
Only one study to date has attempted to validate the Ancona criteria and another slightly 
different set of criteria for SRC that included encephalopathy (12). In that study, a diagnosis of SRC 
confirmed by a study physician was used as the gold standard for SRC. Compared to the gold standard, 
the two sets of criteria identified 70/70 subjects with hypertensive, but only 2/5 subjects with 
normotensive SRC. We believe that our core set, which was developed using robust consensus 
methodology and evidence-based content, represents a significant advancement over these definitions. 
In addition, it defines target organ involvement and provides a detailed histopathological description to 
define the term “findings consistent with SRC”. 
This study has some limitations. First, only 99/216 experts invited to participate accepted and 77 
(78%), 60 (61%) and 69 (70%) of these participated in Rounds 1-3 of the Delphi, respectively. We 
cannot exclude some response bias. Part of the reason for the low response rates may have been that the 
Delphi exercise was conducted during the summer and early fall in the Northern hemisphere. Numerous 
out of office replies were returned. On the other hand, to mitigate this source of bias, reminder emails 
were sent to optimize participation rates and the final sample was still substantial and representative. 
Second, there are large gaps in knowledge on SRC. Hence, participants in the Delphi may have rated 
validity based more on empirical, rather than on scientific evidence. Nevertheless, we provided the 
Delphi participants with the scoping review and all of the original papers included therein in every 
Round for easy access to the available literature. Third, recruitment of participants with a broad range of 
expertise is critical to the success of a consensus-building exercise. Although there were a few 
specialists other than rheumatologists who participated in the Delphi, it became clear at the NGT 
meeting that content expertise in hematology, neurology, ophthalmology, and cardiology was lacking. 
We therefore recruited experts in all of these fields to help finalize the relevant items.
This study has substantial strengths. The emphasis on evidence and input from content experts 
ensured that the final core set had face and content validity. The geographic range of participants 
contributed to the generalizability of the results. There was important complementarity in the use of both 
a Delphi exercise and a semi-structured NGT consensus meeting. The Delphi provided a cost-effective 
approach to survey a larger sample of international experts working anonymously. The NGT meeting 
allowed for a time-efficient, face-to-face discussion of a smaller sample of experts led by an experienced 
moderator.
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Conclusion and future steps
In conclusion, using consensus methodology, we generated a core set of items, and the definition 
of those items, to be used in the development of classification criteria for SRC. To determine if and how 
these items should be incorporated into classification criteria for SRC, two future phases of this research 
project are now in planning. The first, modeled on the International Scleroderma Renal Crisis Survey 
(12), will be to recruit an inception SRC cohort and collect the items in the core set. A comparison 
cohort consisting of subjects with conditions that mimic SRC will also be assembled. These data will be 
used to develop and validate classification criteria for SRC. The second will be a forced choice study 
using multi-criteria decision analysis methods to assign weights to the items in the criteria and to set 
probability values for definite, probable and possible SRC. The resulting classification criteria will 
facilitate rigorous research in SRC. In the meantime, SSc researchers who are designing new studies 
(either observational or trials) are encouraged to collect these items in their datasets. These will be 
useful for future external validation of the criteria.
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Scientific 
Validity
Feasibility
Scientific 
Validity
Feasibility
Systolic blood pressure ≥ 140 mmHg 7(2)* 8(2) 7(1) 8(1) yes
Diastolic blood pressure ≥ 90 mmHg 7(2) 8(1) 7(0.5) 8(1) yes
Rise in systolic blood pressure ≥ 30 
mmHg
7(2) 8(1) 7(1) 8(1) yes
New onset or 
deterioration of pre-
existing hypertension, 
defined as any of the 
following: Rise in diastolic blood pressure ≥ 20 
mmHg
7(2) 8(2) 7(1) 8(0) yes
Increase in both systolic and diastolic blood pressure should be present. 6(3) 8(2) 6(2) 8(0.5) no
Hypertension
In the absence of signs and symptoms, blood pressure measurements 
should be measured on at least 2 occasions.
7(3) 8(1) 7(1) 8(1) yes
Renal insufficiency Increase in serum creatinine ≥50% over baseline or, if no baseline 
available, serum creatinine ≥120%  (or 1.2 times) the upper limit of 
normal for local laboratory (with measurement repeated if necessary to 
rule out lab error).
7(2) 8(2) 7(1) 8(1) yes
New proteinuria defined as ≥ 1+ (30-100 mg/dL range) by urine 
dipstick or worsening proteinuria defined as a ≥ 1 point increase in 
protein on urine (1+ to ≥ 2+, 2+ to ≥ 3+, etc).
5(2) 7(2) 5(1) 7(1) no
New proteinuria defined as ≥ 2+ (100-300 mg/dL range) by urine 
dipstick or worsening proteinuria defined as a ≥ 1 point increase in 
protein on urine (2+ to ≥ 3+, 3+ to ≥ 4+, etc).
7(2) 8(1) 7(1) 8(1) yes
Proteinuria should be confirmed by urine protein:creatinine ratio. 7(2) 8(2) 7(1) 8(0) yes
Proteinuria
Proteinuria should be confirmed by 24-hour urine collection. 6(4) 6(3) 6(2) 6(2) no
New hematuria defined as ≥ 1+ by urine dipstick or worsening 
hematuria defined as a a ≥ 1 point increase on urine dipstick (1+ to ≥ 
2+, 2+ to ≥ 3+, etc).
6(3) 8(1) 6(1) 8(1) no
New hematuria defined as ≥ 2+ by urine dipstick or worsening 
hematuria defined as a ≥ 1 point increase on urine dipstick (2+ to ≥ 3+, 
3+ to ≥ 4+, etc).
6(3) 8(1) 6(1) 8(1) no
Hematuria
New hematuria defined as ≥ 10 red blood cells per high powered field 
on urine microscopy or worsening hematuria defined as a doubling of 
baseline hematuria on urine microscopy.
6(2) 7(2) 6(2) 7(1) no
≤ 100,000 platelets/mm3 6(3) 8(1) 6(1) 8(1) noThrombocytopenia
Thrombocytopenia should be confirmed by manual blood smear. 6(2) 6(2) 6(2) 6(1) no
Schistocytes or other red blood 
cell fragments on blood smear.
8(1) 8(1) 8(0) 8(0) yes
Reticulocyte count above normal 
range for local laboratory.
7(3) 7(1) 7(1) 7(1) yes
Serum lactate dehydrogenase 
and/or indirect bilirubin above 
normal ranges for local 
laboratory.
6(2) 8(2) 6(1) 8(1) no
Hemolysis Microangiopathic hemolytic 
anemia defined as new or 
worsening anemia not due to 
other causes and supported by the 
presence of one of the following:
Serum haptoglobin below normal 
range for local laboratory.
7(2) 8(2) 7(1) 8(1) yes
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Table 1. Results from Rounds 2 and 3 of the Delphi exercise and consensus achieved after Round 3 
- Continued
Microangiopathic hemolytic anemia defined as new or worsening 
anemia not due to other causes and supported by the presence of at 
least two lab abnormalities (red blood cell fragments, elevated 
reticulocyte count, elevated serum lactate dehydrogenase/indirect 
bilirubin, low haptoglobin).
8(1) 8(1) 8(0) 8(0) yes
A direct anti-globulin test should be documented to rule out 
autoimmune hemolytic anemia.
7(3) 7(2) 7(0) 7(1) yes
*  Median values (inter-quartile range) 
Round 2 Round 3
Criteria Category Question Scientific 
Validity
Feasibility
Scientific 
Validity
Feasibility
Consensus
Encephalopathy Encephalopathy defined by the American Academy of Neurology as 
follows: 'Any diffuse disease of the brain that alters brain function or 
structure. The hallmark of encephalopathy is an altered mental state. 
Depending on the type and severity of encephalopathy, common 
neurological symptoms are progressive loss of memory and cognitive 
ability, subtle personality changes, inability to concentrate, lethargy, 
and progressive loss of consciousness. Other neurological symptoms 
may include myoclonus (involuntary twitching of a muscle or group of 
muscles), nystagmus (rapid, involuntary eye movement), tremor, 
muscle atrophy and weakness, dementia, seizures, and loss of ability to 
swallow or speak'.
6(3)* 7(2) 6(1) 7(1) no
Retinopathy typical of malignant hypertension 7(2) 6(3) 7(1) 6(1) noRetinopathy
Grade III (flame-shaped hemorrhages and/or "cotton-wool" exudates) 
or IV (papilledema) retinopathy, according to Keith-Wagener 
classification
7(3) 6(3) 7(1) 6(2) no
Hyperreninemia Elevation of plasma renin activity ≥ 2 times the upper limit of normal 7(3) 4(4) 7(1) 5(2) no
Presence of flash pulmonary edema based on all available information 
and clinical judgement.
6(2) 7(2) 6(1) 7(0) noCardiac dysfunction
Presence of symptomatic pericardial effusion based on all available 
information and clinical judgement.
6(2) 6(2) 6(1) 6(1) no
Findings consistent with scleroderma renal crisis (microangiopathy) 8(2) 6(4) 8(0) 6(2) noAbnormal kidney 
biopsy Accumulation of mucoid (myxoid) in interlobular arteries 
(indistinguishable from accelerated hypertension) and/or fibrinoid 
necrosis of arteries
7(2) 6(4) 7(1) 6(2) noAu
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*  Median values (inter-quartile range) 
Histopathological findings on kidney biopsy consistent with SRC may 
include the following: small vessel (arcuate and interlobular arteries) 
changes predominate over glomerular alterations. Early vascular 
abnormalities include intimal accumulation of myxoid material, 
thrombosis, fibrinoid necrosis, sometimes resulting in cortical necrosis. 
Narrowing and obliteration of the vascular lumen lead to glomerular 
ischemia. Juxtaglomerular apparatus hyperplasia, while relatively rare 
(10%), can be observed. Late changes are manifested by intimal 
thickening and proliferation (which lead to characteristic vascular 
"onion-skin" lesions), glomerulosclerosis and interstitial fibrosis. Since 
none of these findings are specific for scleroderma renal crisis, the 
pathological diagnosis must be supported by appropriate clinical and 
serological data.
8(2) 6(3) 8(0) 6(2) no
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Table 2. Final core set of items to develop classification criteria for SRC
Domain Item
Systolic blood pressure > 140 mmHg
Diastolic blood pressure > 90mmHg
A rise in systolic blood pressure > 30 mmHg above normal
Acute rise in blood 
pressure defined as 
any of the 
following: A rise in diastolic blood pressure > 20 mmHg above normal
Blood pressure
Blood pressure measurement should be taken twice separated by at least 5 minutes. If blood 
pressure readings are discordant, repeat readings should be obtained until 2 consistent readings 
are obtained.
Increase in serum creatinine by > 26.5 umol/L (> 0.3 mg/dl) within 48 
hours
Increase in serum creatinine to >1.5 times baseline, which is known or 
presumed to have occurred within the prior 7 days
Kidney injury* Acute kidney injury 
defined as any of 
the following:
Urine volume < 0.5 ml/kg/h for 6 hours
New or worsening anemia not due to other causes.
Schistocytes or other red blood cell fragments on blood smear.
Thrombocytopenia < 100,000, confirmed by manual smear.
Laboratory evidence of hemolysis, including elevated lactate dehydrogenase, reticulocytosis 
and/or low/absent haptoglobin 
Microangiopathic 
hemolytic anemia 
and 
thrombocytopenia
A negative direct anti-globulin test.
Hypertensive retinopathy (hemorrhages, hard and soft (cotton wool) exudates, and/or disc 
edema, not attributable to other causes), confirmed by an ophthalmologist.
Hypertensive encephalopathy, characterized by headache, altered mental status, seizures, visual 
disturbances and/or other focal or diffuse neurologic signs not attributable to other causes.
Acute heart failure, characterized by typical symptoms (e.g. breathlessness, ankle swelling and 
fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary 
crackles and peripheral edema).
Target organ 
dysfunction
Acute pericarditis, diagnosed with at least 2 of the 4 following criteria: 1) pericarditis chest 
pain; 2) pericardial rub; 3) new widespread ST-elevation or PR depression on 
electrocardiogram; 4) pericardial effusion (new or worsening) on cardiac echocardiography.
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Renal 
histopathology
Histopathological findings on kidney biopsy consistent with scleroderma renal crisis which 
may include the following: small vessel (arcuate and interlobular arteries) changes that 
predominate over glomerular alterations. Glomerular changes of thrombotic microangiopathy 
may be present, with acute changes including fibrin thrombi and endothelial swelling, red 
blood cell fragments and mesangiolysis, and chronic changes including double contours of the 
glomerular basement membrane. Nonspecific ischemic changes with corrugation of the 
glomerular basement membrane, and even segmental or global sclerosis of glomeruli may 
occur. Early vascular abnormalities include intimal accumulation of myxoid material, 
thrombosis, fibrinoid necrosis, fragmented red blood cells, sometimes resulting in cortical 
necrosis. Narrowing and obliteration of the vascular lumen lead to glomerular ischemia. 
Juxtaglomerular apparatus hyperplasia, while relatively rare (10%), can be observed. Late 
changes are manifested by intimal thickening and proliferation (which lead to characteristic 
vascular "onion-skin" lesions), glomerulosclerosis and interstitial fibrosis. Nonspecific tubular 
changes may also occur, including acute tubular injury in the early stage of injury, and later 
interstitial fibrosis and tubular atrophy. Since none of these findings are specific for SRC, the 
pathological diagnosis must be supported by appropriate clinical and serological data.
*This is the definition of acute kidney injury from the Kidney Disease Improving Global Outcomes (KDIGO) guidelines (19)
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